

## Calibrant Biosystems to Present at Tenth Annual C21 BioVentures Conference

Calibrant Biosystems, a biotechnology company specializing in proteomics-based target drug discovery and development, today announced that Michael L. Salgaller, PhD, Chief Operating Officer, will present at the 10<sup>th</sup> Annual C21 BioVentures Conference on Wednesday, May 21, 2008 at 2:45 p.m. Eastern Time. The conference will be held May 21-22, 2008 at the Meritage Resort, Napa, California.

Calibrant Biosystems' presentation will provide a general corporate overview. This will include an update on the Company's proprietary Gemini(TM) proteomics technology, recently validated as capable of sequencing and quantifying thousands of proteins from trace tissue specimens. The proprietary technology allows superior proteomic analysis to explore disease pathogenesis from the level of proteins and their modifications, over multiple biological pathways from isolated and homogeneous populations of disease-relevant cells/tissues. The lead program involves the validation of recurrent, drug-resistant serous epithelial ovarian carcinoma biomarkers from human ascites.

### Contact

Dr. Michael Salgaller  
Chief Operating Officer  
Calibrant Biosystems  
910 Clopper Road, Suite 220N  
Gaithersburg, MD 20878  
Voice: 301-977-7900